Literature DB >> 16172135

Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells.

Francesca Fallarino1, Ciriana Orabona, Carmine Vacca, Roberta Bianchi, Stefania Gizzi, Carine Asselin-Paturel, Maria Cristina Fioretti, Giorgio Trinchieri, Ursula Grohmann, Paolo Puccetti.   

Abstract

Murine plasmacytoid dendritic cells (pDCs) have been credited with a unique ability to express indoleamine 2,3-dioxygenase (IDO) function and mediate immunosuppression in specific settings; yet, the conditions of spontaneous versus induced activity have remained unclear. We have used maneuvers known to up-regulate IDO in different cell types and have examined the relative efficacy and mechanisms of the induced activity in splenic pDCs, namely, after specific receptor engagement by CTLA-4-Ig, CD200-Ig or CD28-Ig, the latter in combination with silenced expression of the suppressor of cytokine signaling 3 (SOCS3) gene. We found that pDCs (CD11c+ mPDCA-1+ 120G8+) do not express IDO and are not tolerogenic under basal conditions. B7-1 engagement by CTLA-4-Ig, CD200R1 engagement by CD200-Ig and B7-1/B7-2 engagement by CD28-Ig in SOCS3-deficient pDCs were each capable of initiating IDO-dependent tolerance via different mechanisms. IFN-gamma was the major cytokine responsible for CTLA-4-Ig effects, and type I IFNs for those of CD200-Ig. Immunosuppression by CD28-Ig in the absence of SOCS3 required IFN-gamma induction and IFN-like actions of IL-6. Therefore, although pDCs do not mediate IDO-dependent tolerance constitutively, multiple ligands and cytokines will contribute to the expression of a tolerogenic phenotype by pDCs in the mouse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16172135     DOI: 10.1093/intimm/dxh321

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  28 in total

1.  Systemic control of plasmacytoid dendritic cells by CD8+ T cells and commensal microbiota.

Authors:  Daisuke Fujiwara; Bo Wei; Laura L Presley; Sarah Brewer; Michael McPherson; Michael A Lewinski; James Borneman; Jonathan Braun
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 2.  Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.

Authors:  Lei Huang; Babak Baban; Burles A Johnson; Andrew L Mellor
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

Review 3.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 4.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

Review 5.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

6.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Authors:  Alexander J Muller; Madhav D Sharma; Phillip R Chandler; James B Duhadaway; Mary E Everhart; Burles A Johnson; David J Kahler; Jeanene Pihkala; Alejandro Peralta Soler; David H Munn; George C Prendergast; Andrew L Mellor
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

7.  Allostimulatory activity of bone marrow-derived plasmacytoid dendritic cells is independent of indoleamine dioxygenase but regulated by inducible costimulator ligand expression.

Authors:  Bridget L Colvin; Tina L Sumpter; Daisuke Tokita; Jennifer Salati; Andrew L Mellor; Angus W Thomson
Journal:  Hum Immunol       Date:  2009-02-03       Impact factor: 2.850

8.  High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway.

Authors:  Claudia Volpi; Francesca Fallarino; Maria T Pallotta; Roberta Bianchi; Carmine Vacca; Maria L Belladonna; Ciriana Orabona; Antonella De Luca; Louis Boon; Luigina Romani; Ursula Grohmann; Paolo Puccetti
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis.

Authors:  Ciriana Orabona; Maria T Pallotta; Claudia Volpi; Francesca Fallarino; Carmine Vacca; Roberta Bianchi; Maria L Belladonna; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

Review 10.  T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.

Authors:  David J Kahler; Andrew L Mellor
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.